Document Detail


Update on medications with adverse skeletal effects.
MedLine Citation:
PMID:  21389249     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients rely on their primary care physician to manage multiple, often chronic medical conditions that require prescription medications. Balancing the risk to benefit of treatments can be challenging and requires that the primary care physician stay abreast of new information regarding risks and benefits. The number of medications with reported adverse effects on skeletal health is expanding. This review focuses on medications recently added to the list of "bad to the bone" drugs and on recent advances in management of glucocorticoid-induced osteoporosis. A practical approach to assessing and managing the skeletal risks is outlined.
Authors:
Caroline J Davidge Pitts; Ann E Kearns
Related Documents :
6721459 - Incidence, pattern and direction of hair distribution on the dorsum of phalanges of the...
10372849 - Centennial year of ronald ross' epic discovery of malaria transmission: an essay and tr...
15015549 - Conference round-up 2003: historians and war.
21188679 - Retrospective analysis of stimulant abuse cases reported to the swiss toxicological inf...
21393399 - Stenting versus medical treatment for severe symptomatic intracranial stenosis.
6507609 - Polymorphism of palmar c- and d-line terminations among the sikligars of chandigarh.
17095179 - Measuring patient and physician participation in exchanges on medications: dialogue rat...
17017469 - Medical devices; reprocessed single-use devices; requirement for submission of validati...
15028799 - Primer on medical professionalism.
Publication Detail:
Type:  Journal Article; Review     Date:  2011-03-09
Journal Detail:
Title:  Mayo Clinic proceedings. Mayo Clinic     Volume:  86     ISSN:  1942-5546     ISO Abbreviation:  Mayo Clin. Proc.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-01     Completed Date:  2011-06-23     Revised Date:  2012-05-07    
Medline Journal Info:
Nlm Unique ID:  0405543     Medline TA:  Mayo Clin Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  338-43; quiz 343     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aromatase Inhibitors / adverse effects,  therapeutic use
Bone Density / drug effects
Bone and Bones / drug effects*
Breast Neoplasms / drug therapy
Contraceptive Agents, Female / adverse effects
Diphosphonates / therapeutic use
Fractures, Bone / chemically induced
Glucocorticoids / adverse effects
Gonadotropin-Releasing Hormone / agonists
Humans
Medroxyprogesterone Acetate / adverse effects
Osteoporosis / chemically induced*,  drug therapy
Peroxisome Proliferator-Activated Receptors / agonists
Proton Pump Inhibitors / therapeutic use
Serotonin Uptake Inhibitors / adverse effects,  therapeutic use
Thiazolidinediones / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Aromatase Inhibitors; 0/Contraceptive Agents, Female; 0/Diphosphonates; 0/Glucocorticoids; 0/Peroxisome Proliferator-Activated Receptors; 0/Proton Pump Inhibitors; 0/Serotonin Uptake Inhibitors; 0/Thiazolidinediones; 33515-09-2/Gonadotropin-Releasing Hormone; 71-58-9/Medroxyprogesterone Acetate
Comments/Corrections
Comment In:
Mayo Clin Proc. 2011 Sep;86(9):916   [PMID:  21878606 ]
Mayo Clin Proc. 2011 Sep;86(9):916-7; author reply 917   [PMID:  21878605 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Medication adherence among community-dwelling patients with heart failure.
Next Document:  Medication adherence: WHO cares?